Anakinra
(Synonyms: 阿那白滞素; AMG-719) 目录号 : GC39339阿那白滞素(Anakinra)是一种重组的、非糖基化的人类白细胞介素-1受体拮抗剂（IL-1Ra）。
Cas No.:143090-92-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Anakinra (AMG-719, Raleukin) is a recombinant, non glycosylated human interleukin-1 receptor antagonist (IL-1Ra). It is produced using DNA recombination technology in the Escherichia coli expression system andamino acid sequence is MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE. Anakinra represents the inaugural biological therapy designed to neutralize the inflammatory actions of IL-1[1][2]. Anakinra has been proven effective for the treatment of various inflammatory and autoimmune diseases, including Still's disease[3].
Anakinra was administered at a dose of 100 mg/kg via intraperitoneal injection, and the same route was used to administer Etanercept at a dose of 5 mg/kg daily for seven consecutive days, which significantly facilitated the successful implantation of marginal quality human islet cells in mice with impaired immune systems [2]. Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and treated with beta-(1-3),(1-6)-D-glucan by blocking the IL-1 receptor and reducing IL-1-induced IL-6 production[4].
References:
[1] Cvetkovic RS, et al. Anakinra. BioDrugs. 2002;16(4):303-11; discussion 313-4.
[2] McCall M, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant. 2012 Feb;12(2):322-9.
[3] Vastert Sebastiaan J, et al. Anakinra in children and adults with Still's disease. Rheumatology (Oxford) 2019 Nov 1;58(Suppl 6):vi9-vi22. PMID:31769856. DOI:10.1093/rheumatology/kez350.
[4] Harnack U, et al. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan. Anticancer Res. 2010 Oct;30(10):3959-65.
阿那白滞素(Anakinra)是一种重组的、非糖基化的人类白细胞介素-1受体拮抗剂（IL-1Ra）。它是利用大肠杆菌表达系统的DNA重组技术生产的，并且氨基酸序列为MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE。阿那白滞素代表了首个旨在中和IL-1炎症作用的生物疗法[1][2]。阿那白滞素已被证明可用于治疗斯蒂尔病等多种炎症和自身免疫性疾病[3]。
阿那白滞素通过腹腔注射100 mg/kg，以及相同途径每日给予依那西普（Etanercept）5 mg/kg的剂量，连续7天，显著促进了在免疫系统受损的小鼠中，边缘质量的人类胰岛细胞的成功植入[2]。阿那白滞素通过阻断 IL-1 受体来减少 IL-1 诱导的 IL-6 生成，增强了接受肽疫苗接种并经β-(1-3),(1-6)-D-葡聚糖处理的小鼠中肿瘤生长的抑制[4]。
| Animal experiment [1]: | |
|
Animal models |
Immunodeficient mice |
|
Preparation Method |
The simultaneous administration of Etanercept (at a dosage of 5 mg/kg, via intraperitoneal injection) coupled with daily Anakinra (at a dosage of 100 mg/kg, also via intraperitoneal injection for a period of 7 days). |
|
Dosage form |
100 mg/kg, daily for 7 days, intraperitoneal injection |
|
Applications |
The simultaneous administration of Etanercept coupled with daily Anakinra significantly enhanced the engraftment of marginal mass human islets in immunodeficient mice. |
|
References: |
|
| Cas No. | 143090-92-0 | SDF | |
| 别名 | 阿那白滞素; AMG-719 | ||
| Canonical SMILES | [Anakinra] | ||
| 分子式 | C759H1186N208O232S10 | 分子量 | 17257.6 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at 4°C, do not freeze |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0579 mL | 0.2897 mL | 0.5795 mL |
| 5 mM | 0.0116 mL | 0.0579 mL | 0.1159 mL |
| 10 mM | 0.0058 mL | 0.029 mL | 0.0579 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity:≥95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet